Shukra Pharmaceuticals Ltd
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap ₹ 1,126 Cr.
- Current Price ₹ 25.7
- High / Low ₹ 27.2 / 5.75
- Stock P/E 111
- Book Value ₹ 1.44
- Dividend Yield 0.39 %
- ROCE 21.8 %
- ROE 15.9 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 244% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.6%
- Debtor days have improved from 135 to 98.2 days.
Cons
- Stock is trading at 17.9 times its book value
- Earnings include an other income of Rs.4.61 Cr.
- Working capital days have increased from 201 days to 404 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | 3 | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 | 75 | 33 | 35 | |
5 | 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 | 55 | 20 | 22 | |
Operating Profit | -0 | -0 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 5 | 19 | 13 | 13 |
OPM % | -2% | -10% | 24% | 28% | 30% | 29% | 13% | 13% | 14% | 9% | 26% | 39% | 38% |
0 | 1 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 5 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Depreciation | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 |
Profit before tax | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 13 | 14 |
Tax % | 9% | 52% | 66% | 52% | 45% | 37% | 82% | -90% | 26% | 1% | 7% | 28% | |
-1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 19 | 10 | 10 | |
EPS in Rs | -0.02 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.10 | 0.42 | 0.22 | 0.22 |
Dividend Payout % | 0% | 0% | 0% | 16% | 15% | 17% | 0% | 0% | 10% | 4% | 6% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 29% |
5 Years: | 22% |
3 Years: | 17% |
TTM: | -40% |
Compounded Profit Growth | |
---|---|
10 Years: | 53% |
5 Years: | 244% |
3 Years: | 134% |
TTM: | -46% |
Stock Price CAGR | |
---|---|
10 Years: | 57% |
5 Years: | 162% |
3 Years: | 187% |
1 Year: | 290% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 22% |
3 Years: | 27% |
Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 | 44 |
Reserves | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 47 | 19 |
0 | 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 5 | 3 | 4 | |
4 | 3 | 3 | 4 | 6 | 7 | 10 | 10 | 15 | 45 | 17 | 20 | |
Total Liabilities | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 |
10 | 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | 19 | |
CWIP | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
7 | 7 | 6 | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 56 | 65 | |
Total Assets | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-3 | -2 | 3 | -0 | 1 | 0 | 1 | 1 | 8 | 3 | -5 | 8 | |
-10 | 1 | -0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 | -1 | -1 | |
-18 | 1 | -1 | 0 | 3 | 2 | 2 | 2 | -7 | 5 | 12 | -5 | |
Net Cash Flow | -31 | 0 | 1 | -1 | -0 | 0 | -0 | 0 | -0 | 4 | 6 | 2 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 45 | 73 | 71 | 175 | 200 | 345 | 245 | 318 | 132 | 187 | 120 | 98 |
Inventory Days | 134 | 554 | 92 | 112 | 53 | 100 | 169 | 221 | 139 | 25 | 19 | 447 |
Days Payable | 209 | 291 | 108 | 400 | 734 | 1,161 | 786 | 702 | 303 | 271 | 59 | 414 |
Cash Conversion Cycle | -30 | 335 | 54 | -112 | -480 | -717 | -372 | -163 | -32 | -58 | 80 | 131 |
Working Capital Days | 368 | 758 | 258 | 344 | 379 | 440 | 226 | 278 | 57 | 41 | 157 | 404 |
ROCE % | -6% | -1% | 6% | 7% | 6% | 4% | 0% | 1% | 6% | 19% | 44% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
2m - Company has received Letter of Award(LOA).
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Aug - Publication of Financial results for the quarter ended June 2025
-
Un-Audited Financial Results Of The Company For The First Quarter Ended June 30, 2025, Along With The Auditors' Limited Review Reports In Accordance With The Provisions Of Regulation 33 Of The SEBI Listing Regulations.
13 Aug - Q1 FY2025 unaudited results approved; net profit Rs. 102.96 lakhs; business reviewed by board.
-
Board Meeting Outcome for Outcome Of The Meeting Of The Board Held On Wednesday, August 13, 2025.
13 Aug - Q1 FY2026 unaudited financial results approved; net profit Rs. 102.96 lakhs reported.
-
Board Meeting Intimation for Meeting Of The Board Of The Company Is Scheduled To Be Held On August 13, 2025
31 Jul - Board meeting on Aug 13, 2025 to approve Q1 June 30 unaudited financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies